Journal: Wiener klinische Wochenschrift

Article Title: Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm.

PMID/MRN: 27743175

Publication Date: 2016-Oct-14

Abstract:

Patients with aplastic anemia or hypoplastic myelodysplastic syndrome (MDS) may respond to immunosuppressive therapy, including the anti-CD52 antibody alemtuzumab. We analyzed treatment responses to alemtuzumab in 5Êpatients with MDS or aplastic anemia (AA) evolving to MDS. Two patients with hypoplastic MDS (hMDS) showed a partial response (PR) to alemtuzumab. In both responding patients, a concomitant paroxysmal nocturnal hemoglobinuria (PNH) clone was detected before therapy. One responder relapsed after 15Êmonths and underwent successful allogeneic stem cell transplantation. Both patients are still alive and in remission after 40 and 20Êmonths, respectively. The other patients showed no response to alemtuzumab. One patient died from pneumonia 4Êmonths after treatment. In summary, our data confirm that alemtuzumab is an effective treatment option for a subset of patients with MDS, even in the presence of a PNH clone.